Loading
myeloMATCH is a US-wide master trial that sequences every new leukaemia within days and routes the patient to the right experimental arm, then re-routes them as MRD results come in.
Launched 2024 across ~200 sites. Rapid central genomics (results in 72 hours) and MRD assessments at each 'tier' allow patients to move between sub-studies (e.g., FLT3, TP53, NPM1, older-unfit cohorts) testing venetoclax, menin inhibitors, FLT3 inhibitors, magrolimab successors, and CPX-351. The infrastructure model for precision leukaemia trials.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares MRD-guided transplant decisions in intermediate-risk AML, IDH1- and IDH2-mutated acute myeloid leukaemia, FLT3-mutated acute myeloid leukaemia, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia.
Shares IDH1- and IDH2-mutated acute myeloid leukaemia, FLT3-mutated acute myeloid leukaemia, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia, Secondary and therapy-related acute myeloid leukaemia.
Shares NCI-MATCH (EAY131), Master protocol (platform, basket and umbrella trials), Basket, umbrella, and platform trials, Trial design, endpoints and cost.
Shares IDH1- and IDH2-mutated acute myeloid leukaemia, FLT3-mutated acute myeloid leukaemia, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia, Secondary and therapy-related acute myeloid leukaemia.
Shares CPX-351 (liposomal daunorubicin-cytarabine), Secondary and therapy-related acute myeloid leukaemia, Acute myeloid leukaemia in older or unfit patients, Venetoclax.
Shares Response-adaptive randomisation, Seamless, adaptive and Bayesian trial designs, Master protocol (platform, basket and umbrella trials), Basket, umbrella, and platform trials.
Shares IDH1- and IDH2-mutated acute myeloid leukaemia, FLT3-mutated acute myeloid leukaemia, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia, Secondary and therapy-related acute myeloid leukaemia.
Shares Umbrella trial, NCI-MATCH (EAY131), Seamless, adaptive and Bayesian trial designs, Master protocol (platform, basket and umbrella trials).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/